EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: KIF5B-ALK–rearranged renal cell carcinoma

Jiaxi Yao, Zhifei Xie, Guangyao Shi, Ming Tan, Zhuo Liu, Min Lu, Hongxian Zhang

Frontiers in Oncology · 15.06.2026 · 16

DOI: 10.3389/fonc.2026.1825447 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 15.06.2026. Verfasst von Jiaxi Yao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Zhangye People's Hospital Affiliated to Hexi University, Zhangye, China. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anaplastic lymphoma kinase (ALK)–rearranged renal cell carcinoma (ALK-RCC) is a rare provisional entity characterized by fusion of the ALK gene with various fusion partner genes, resulting in oncogenic activation. Case presentation We report a case of a 39-year-old Chinese man with ALK-RCC who underwent partial nephrectomy for a left renal tumor measuring 2.8 × 2.7× 2.6 cm. Histopathological examination revealed a renal epithelial tumor with atypical morphology. Immunohistochemistry demonstrated the occurrence of renal epithelial differentiation and excluded other entities. Next-generation sequencing confirmed a KIF5B-ALK gene fusion.

Conclusion

This case presents the clinical data, morphology, immunohistochemistry, and molecular characteristics of a rare subtype of ALK–rearranged renal cell carcinoma with KIF5B-ALK fusion. The findings may enhance the clinical and pathological understanding of ALK-RCC among clinicians and pathologists. Managing ALK-RCC is challenging due to its rarity and limited treatment options. Targeted therapies directed at the ALK gene may have a role in patients with ALK-RCC.

Schlagwörter

Stichwörter der Autor:innen

KIF5Banaplastic lymphoma kinasecase reportrarerenal cell carcinoma

Autor:innen und Institutionen

  • Department of Urology, Zhangye People's Hospital Affiliated to Hexi University, Zhangye, China.
  • Institute of Urology, Hexi University, Zhangye, China.
  • Department of Urology, Wuqing District Second People's Hospital, Tianjin, China.
  • Department of Urology, Chengwu County People's Hospital, Heze, China.
  • Department of Urology, Peking University Third Hospital, Beijing, China.
  • Department of Pathology, Peking University Third Hospital, Beijing, China.

Zitieren

APA

Yao, J., Xie, Z., Shi, G., Tan, M., Liu, Z., Lu, M., & Zhang, H. (2026). Case Report: KIF5B-ALK–rearranged renal cell carcinoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1825447

Vancouver

Yao J, Xie Z, Shi G, Tan M, Liu Z, Lu M, et al. Case Report: KIF5B-ALK–rearranged renal cell carcinoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1825447

BibTeX
@article{Yao2026,
  author = {Yao, Jiaxi and Xie, Zhifei and Shi, Guangyao and Tan, Ming and Liu, Zhuo and Lu, Min and Zhang, Hongxian},
  title = {Case Report: KIF5B-ALK–rearranged renal cell carcinoma},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1825447}
}
Kostenlos starten →